Patent intelligence · CA
CA 3089552
PROCEDE CONTINU DE PREPARATION DE TRAZODONE
PROCEDE CONTINU DE PREPARATION DE TRAZODONE
Patent details — CA 3089552
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Aug 15, 2019
- Expiration
- Aug 10, 2039
- CPC classes
- A61K/31496, A61P/2524
Quick answer
CA 3089552 (PROCEDE CONTINU DE PREPARATION DE TRAZODONE) is held by AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO ACRAF SPA [IT]. Status: granted. Granted Aug 15, 2019. Expires Aug 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/31496, A61P/2524
More from AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO ACRAF SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
EP 3807294
PEPTIDE MIT HEMMENDER WIRKUNG AUF MUSKARINREZEPTOR M3
granted -
EP 3807293
PEPTIDE MIT HEMMENDER WIRKUNG AUF NEURONALE EXOZYTOSE
granted -
CA 3135097
COMBINAISON PHARMACEUTIQUE COMPRENANT DE LA TRAZODONE POUR LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
granted -
WO 2020178316
AZAINDAZOLES EN 5 OU 7 UTILISÉS COMME INHIBITEURS DE BÊTA-LACTAMASE
granted -
WO 2020074463
COMPOSITION LIQUIDE ORALE COMPRENANT DU TRIPTAN
granted -
CA 3094896
COMPOSES DE 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE LA GLYCOGENE SYNTHASE KINASE 3 BETA
granted -
CA 3079530
COMPOSITION LIQUIDE STABLE DE KETOPROFENE, SELS ET ENANTIOMERES DE CELUI-CI
granted
Frequently asked questions
What is US patent 3089552?
CA 3089552 (PROCEDE CONTINU DE PREPARATION DE TRAZODONE) is held by AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO ACRAF SPA [IT]. Status: granted. Granted Aug 15, 2019. Expires Aug 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3089552?
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO ACRAF SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3089552 expire?
Our index shows an expiration date of Aug 10, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.